PRAXHealthcare · BiotechnologyThe 19 Wall Street analysts covering Praxis Precision Medicines, Inc. hold a median 12-month price target of $550 — +49.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 51 of 100 as at 13 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Praxis Precision Medicines, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (93): The shares have been drifting up relative to others.
Issuance (26): The company has been issuing shares or taking on financing, diluting existing holders.
Size (16): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PRAX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +49.9% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Aug 2026 | RBC Capital | Maintains | Outperform | $449 → $462 |
| 7 Aug 2026 | Wells Fargo | Maintains | Equal-Weight | $323 → $362 |
| 6 Aug 2026 | Needham | Maintains | Buy | $575 → $582 |
| 29 July 2026 | BTIG | Reiterates | Buy | $810 |
| 29 July 2026 | BTIG | Reiterates | Buy | — |
| 13 July 2026 | Goldman Sachs | Initiates | Buy | $447 |
| 13 July 2026 | Goldman Sachs | Initiates | Buy | — |
| 29 June 2026 | Needham | Maintains | Buy | — |
| 18 June 2026 | RBC Capital | Initiates | Outperform | — |
| 2 June 2026 | Baird | Maintains | Outperform | — |
| 2 June 2026 | BTIG | Maintains | Buy | — |
| 2 June 2026 | Deutsche Bank | Maintains | Buy | — |
| 2 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 2 June 2026 | Oppenheimer | Maintains | Outperform | — |
| 2 June 2026 | Truist Securities | Maintains | Buy | — |
| 2 June 2026 | Wedbush | Maintains | Underperform | — |
| 26 May 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 May 2026 | BTIG | Reiterates | Buy | — |
| 13 May 2026 | Truist Securities | Maintains | Buy | — |
| 8 May 2026 | BTIG | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PRAX appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 97% of US stocks
Cheaper than 14% of US stocks
Cheaper than 90% of US stocks
Higher than 33% of US stocks
Higher than 30% of US stocks
Higher than 24% of US stocks
Higher than 16% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Praxis Precision Medicines, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research highlighted Praxis Precision Medicines as one of four biotech stocks with major second-half pipeline catalysts this year, including potential FDA decisions and late-stage data readouts.
Why it matters — PRAX watchers would care because the article points to upcoming pipeline events and regulatory catalysts for the company in the latter part of the year.
A Seeking Alpha video analyzes Praxis Precision Medicines using a sum-of-parts valuation approach, focusing on its lead asset, Ulixa. It highlights updates from a Goldman Sachs presentation on key developments and upcoming catalysts ahead of Ulixa's commercial launch, assessing PRAX's strategic positioning around the product's market entry.
Why it matters — PRAX watchers would care because the analysis centers on Ulixa's commercial launch and the upcoming catalysts tied to entering the market.
Praxis Precision Medicines, Inc. (PRAX) held its Q2 2026 earnings call, and the transcript was published by Seeking Alpha. The item announces the availability of the company's second-quarter 2026 earnings discussion.
Why it matters — A PRAX watcher would care because the transcript provides a record of management's commentary on the company's Q2 2026 financial results and business developments.
Praxis Precision Medicines reported that it is preparing for potential commercial launches of ulixacaltamide for essential tremor and relutrigine for SCN2A- and SCN8A-related DEEs while both NDAs remain under FDA review.
Why it matters — A PRAX watcher would care because the company is moving toward commercialization of two pipeline candidates, signaling potential near-term revenue opportunities if FDA approvals are granted.
Seeking Alpha introduced 33 new analysts in July 2026 and published their top picks and investment strategies, highlighting companies such as SELLAS Life Sciences, Chevron, B2Gold, Amazon, and QXO, with theses touching on asymmetric opportunities, event-driven catalysts, balance sheet strength, market structure, and sector-specific factors.
Why it matters — Praxis Precision Medicines is not mentioned in the article, so it offers no direct PRAX-specific information, though a PRAX watcher may note the broader analyst and market coverage landscape.
The 19 Wall Street analysts covering Praxis Precision Medicines, Inc. have a median 12-month price target of $550, with estimates ranging from $188 to $1,201. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 19 analysts covering Praxis Precision Medicines, Inc., 17 rate it a Buy, 1 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Praxis Precision Medicines, Inc. 51 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Aug 2026, Praxis Precision Medicines, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (93 of 100).
No one can know that. What the data says: the median 12-month target from 19 analysts implies +49.9% from the last close, and Ticker Nerd's factor model ranks Praxis Precision Medicines, Inc. 51 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Praxis Precision Medicines, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PRAX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $188 to $1,201 over the next 12 months.
Praxis Precision Medicines, Inc. returned +669.0% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Praxis Precision Medicines Inc. operates within the biopharmaceutical sector, focusing on the development of treatments for central nervous system (CNS) disorders.
The most recent item we track (Zacks Investment Research, 11 Aug 2026): "4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year". Zacks Investment Research highlighted Praxis Precision Medicines as one of four biotech stocks with major second-half pipeline catalysts this year, including potential FDA decisions and late-stage data readouts.
Praxis Precision Medicines Inc. operates within the biopharmaceutical sector, focusing on the development of treatments for central nervous system (CNS) disorders. The company's primary objective is to address unmet medical needs by leveraging their extensive research in genetics, the neurobiology of CNS disorders, and translational science. Praxis Precision Medicines is rapidly carving out a niche in the healthcare field by targeting illnesses such as epilepsy, movement disorders, and psychiatric conditions, which impact millions of individuals globally. Their innovative pipeline includes a variety of therapeutic candidates designed to modulate specific neural pathways that are believed to be core to CNS dysregulation. As an emerging leader in the biopharma industry, Praxis Precision Medicines plays a crucial role in advancing CNS treatment paradigms, working to improve quality of life for patients and expand the possibilities of personalized medicine through cutting-edge science.
CEO Mr. Marcio Silva De'Souza M.B.A. · 168 employees · United States · https://praxismedicines.com